搜索
ss
ss
关于普米斯
About Us
z346

Steven Wang (Director)

CEO of HLC (Highlight Capital). Previously enrolled at USTC (University of Science and Technology of China), NYU (New York University), and LBS (London Business School). Once served in CHD, Avenue Capital (USA), Lehman Brothers (London Branch), and Becton Dickinson Healthcare Group (USA). Steven founded HLC in 2014 and manages 6 dual-currency funds (RMB/USD) a total of more than RMB 12 billion. His investment projects include Yuwell (002223), Wuxi Apptech (603259), Nayuki (02150), Mindray (300760), Pharmaron (300759), Tigermed (03347), Bright Gene (688166) and United Imagine, etc. He was awarded as Top 10 Best Investors in Healthcare in China for 2014-2019, Forbes Best Venture Capitalist in China for 2019, Top 100 Investor of Zero2IPO Investment Community in 2020.
z346
Product description
Parameters

CEO of HLC (Highlight Capital). Previously enrolled at USTC (University of Science and Technology of China), NYU (New York University), and LBS (London Business School). Once served in CHD, Avenue Capital (USA), Lehman Brothers (London Branch), and Becton Dickinson Healthcare Group (USA). Steven founded HLC in 2014 and manages 6 dual-currency funds (RMB/USD) a total of more than RMB 12 billion. His investment projects include Yuwell (002223), Wuxi Apptech (603259), Nayuki (02150), Mindray (300760), Pharmaron (300759), Tigermed (03347), Bright Gene (688166) and United Imagine, etc. He was awarded as Top 10 Best Investors in Healthcare in China for 2014-2019, Forbes Best Venture Capitalist in China for 2019, Top 100 Investor of Zero2IPO Investment Community in 2020.

Keyword:
董事
医疗
医药
美国
投资人
先后
资本
中国
人民币
最佳
Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
There is currently no content to display
Please add data record on website background.

Copyright: © 2021 Biotheus, Inc.     粤ICP备2021122492号      Powered by www.300.cn